The Department of Health and Human Services has introduced an updated national strategy to combat Alzheimer’s disease and related dementias, emphasizing lifelong risk reduction, earlier diagnosis, accelerated medical research and expanded support for patients and caregivers.
By yourNEWS Media Newsroom
The Department of Health and Human Services announced a comprehensive update to its national Alzheimer’s disease strategy Thursday, Oct. 22, shifting greater attention toward preventing or delaying dementia, improving early detection and developing more effective treatments.
Health Secretary Robert F. Kennedy Jr. unveiled the 2026 National Plan to Address Alzheimer’s Disease and Related Dementias during an event at Broward Health Medical Center in Fort Lauderdale, Florida.
The updated plan replaces six previous national objectives with four broader goals designed to coordinate federal efforts across prevention, scientific research, clinical care and assistance for families affected by dementia.
“Millions of American families have seen the devastating toll of Alzheimer’s disease and related dementias,” Kennedy said. “Under President Trump, HHS is shifting the national strategy toward prevention, earlier detection, and faster development of better diagnostics and treatments. We are advancing gold-standard science, reducing risk where we can, improving care, and giving patients and families stronger support at every stage of the disease.”
A central feature of the revised strategy is reducing dementia risk throughout a person’s lifetime rather than concentrating exclusively on treatment after cognitive impairment develops.
Federal health officials plan to expand research into risk factors that may contribute to Alzheimer’s and related conditions while improving efforts to translate scientific findings into preventive health practices.
The approach recognizes that certain factors associated with dementia, including cardiovascular health, physical inactivity and metabolic disorders, may offer opportunities for intervention before significant cognitive decline occurs.
However, reducing individual risk factors does not guarantee that dementia can be prevented. Alzheimer’s disease remains a complex neurological condition influenced by age, genetics and other biological and environmental factors.
The second major objective focuses on accelerating scientific discoveries, including research into biomarkers, diagnostic technologies, clinical trials and therapies intended to prevent or slow disease progression.
Improved diagnostic tools could help physicians identify changes associated with Alzheimer’s earlier, potentially allowing patients to receive treatment and support before symptoms become severe.
The third goal seeks to improve the quality and coordination of dementia care, from initial evaluation and diagnosis through treatment, disease management and transitions between medical or long-term care settings.
The fourth concentrates on strengthening services for people living with dementia and their families, including caregiver education, respite care, safety planning and community-based assistance.
The updated strategy also places greater emphasis on populations and communities that experience higher dementia risks or face barriers to obtaining timely diagnosis and treatment.
HHS said 10 federal agencies are participating in initiatives supporting the plan.
Among the most significant developments is a new Food and Drug Administration effort to accelerate research into preventing Alzheimer’s disease.
The FDA announced Thursday that it has established the Neuroscience Advancement and Innovation Nexus, a program designed to coordinate scientific and regulatory expertise across medical products involving the brain and nervous system.
Its initial project, the Alzheimer’s Prevention Accelerator, will focus on developing approaches to help prevent or delay Alzheimer’s disease.
The initiative will explore new clinical trial methods, including how researchers select participants, measure outcomes and demonstrate whether experimental treatments meaningfully delay cognitive decline.
The FDA plans to coordinate expertise across its drug, biologics and medical device divisions while consulting researchers, patients, caregivers and private-sector developers.
“The launch of NAIN reflects FDA’s commitment — in support of the Trump Administration’s drive to transform health care innovation — to making sure our regulatory science and cross-center collaboration keep pace with the rapid advances happening in neuroscience,” acting FDA Commissioner Kyle Diamantas said.
HHS also announced additional funding through the Advanced Research Projects Agency for Health, which is investing up to $48.8 million in new projects focused on earlier detection and medical intervention.
Those awards complement existing Alzheimer’s-related research initiatives at the agency, bringing the combined potential investment to approximately $155.3 million.
Other federal efforts will expand dementia screening and training in community health centers, develop behavioral health resources for older adults experiencing cognitive decline and strengthen public health education concerning brain health.
The Administration for Community Living will also expand training and resources for professionals responsible for protecting vulnerable older adults.
Meanwhile, the Centers for Medicare & Medicaid Services is pursuing programs intended to ease the financial and practical burdens associated with dementia care.
“The human and financial costs of Alzheimer’s and dementia care are growing at unacceptable rates, and this updated national plan addresses both,” CMS Administrator Dr. Mehmet Oz said.
“Through initiatives that ease the burden on caregivers and expand access to lifestyle medicine interventions that help slow cognitive decline, CMS is conserving public health dollars, promoting human dignity, and giving American families more good years with the people they love.”
The financial consequences of Alzheimer’s and other dementias remain substantial. According to the Alzheimer’s Association’s 2026 estimates, health care, long-term care and hospice costs for Americans living with these conditions are projected to reach $409 billion this year, excluding the economic value of unpaid family caregiving.
The revised strategy builds on the National Alzheimer’s Project Act, enacted in 2011 to establish a coordinated federal response to Alzheimer’s disease.
HHS previously added a national goal addressing healthy aging and dementia risk reduction in 2021. The new plan expands that emphasis while reorganizing the government’s objectives around the progression of brain health and disease.
The department said the updated strategy includes priorities for 2027, when federal agencies will evaluate progress toward each of the four goals and publish findings in the next annual report.
Although the plan does not announce a cure for Alzheimer’s disease, it establishes a broader federal approach aimed at delaying disease onset, improving access to diagnosis and treatment, and reducing the burden on patients and families.
HHS officials said the objective is to translate advances in neuroscience into measurable improvements in prevention, care and quality of life for Americans affected by dementia.
Original article
Comments